journal article·2025-10

Integration of Multi‐Rotor and Multi‐Conjugation: Ultrahigh Absorption Coefficient Dye Enables NIR‐II Fluorescence Imaging‐guided Photothermal Immunotherapy

Guining Cao, Jiacheng Tang, Meijing Wang, Qitong Qin, Hongshan Xie, Zhenxing Pan, Jiapeng Dong, Junze Tang, Huiling Ye, Yaoxun Zeng, Hailiang Zhang, Mei‐ling Deng, Xiang Su, Yan He, Xin Cheng, Xujie Liu

Small· Volume 21· Issue 40
Publisher page

Abstract

Abstract The progressive accumulation of mutated genes in cancer cells facilitates tumor immune escape. Photothermal immunotherapy addresses this problem by triggering immunogenic cell death (ICD) through photothermal treatment, releasing endogenous immunogenic neoantigens. Herein, guided by the “multi‐rotor & multi‐conjugation” concept, near‐infrared region II (NIR‐II) cyanine molecules are designed with varying numbers of benzene rotors. TPE‐CyA, with more benzene rotors, features an ultra‐high molar extinction coefficient (1.786 × 10 5 m −1 cm −1 ), a well‐balanced fluorescence quantum yield (0.99%), and a 45.72% photothermal conversion efficiency. TPE‐CyA nanoparticles (TPE‐CyA NPs) are ideal for high‐resolution NIR‐II fluorescence imaging and angiography. Imaging‐guided TPE‐CyA NPs show great potential in NIR‐II photothermal immunotherapy by effectively suppressing bilateral tumor growth and liver metastasis without additional immunoadjuvants. Moreover, the photothermal immunotherapy guided by TPE‐CyA NPs can induce ICD, promote dendritic cell (DCs) maturation, increase T‐cell infiltration in tumors, and activate systemic immunity to prevent metastasis and recurrence. This research highlights the potential of NIR‐II photothermal therapy in tumor cell ablation, immune activation for cancer and vascular diagnostics, presenting a novel strategy for both primary and metastatic cancers.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Extracellular vesicles in disease

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Biomedical and Pharmaceutical Sciences Guangdong University of Technology Guangzhou Guangdong 510060 China

College of Traditional Chinese Medicine Yunnan University of Chinese Medicine Kunming Yunnan 650500 China

Department of Radiation Oncology State Key Laboratory of Oncology in South China Sun Yat‐sen University Cancer Center Guangzhou Guangdong 510050 China

Funding

National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province

References (42)

Show source-provided references
1. 10.1007/s11434-015-0794-z10.1007/s11434-015-0794-z ↗
2. 10.1126/science.120348610.1126/science.1203486 ↗
3. 10.1038/nature1075510.1038/nature10755 ↗
4. 10.1002/cac2.1217810.1002/cac2.12178 ↗
5. 10.1038/s41577-019-0218-410.1038/s41577-019-0218-4 ↗
6. 10.1016/j.biomaterials.2022.12172210.1016/j.biomaterials.2022.121722 ↗
7. 10.1016/j.jare.2024.06.01110.1016/j.jare.2024.06.011 ↗
8. 10.1021/acsnano.3c1102310.1021/acsnano.3c11023 ↗
9. 10.1016/j.jconrel.2024.07.02410.1016/j.jconrel.2024.07.024 ↗
10. Yang C. · Adv. Funct. Mater. · 2023 · 4 · 33
11. 10.1021/acsami.5c0018410.1021/acsami.5c00184 ↗
12. 10.1016/j.cclet.2025.11103110.1016/j.cclet.2025.111031 ↗
13. 10.1016/j.jconrel.2023.11.00810.1016/j.jconrel.2023.11.008 ↗
14. 10.1002/smll.20230576410.1002/smll.202305764 ↗
15. 10.1016/j.jconrel.2024.03.02010.1016/j.jconrel.2024.03.020 ↗
16. 10.1039/D1CS00543J10.1039/D1CS00543J ↗
17. 10.1016/j.ccr.2024.21586610.1016/j.ccr.2024.215866 ↗
18. 10.1038/s41571-024-00892-010.1038/s41571-024-00892-0 ↗
19. 10.1039/D0BM00249F10.1039/D0BM00249F ↗
20. 10.1002/smll.20230100310.1002/smll.202301003 ↗
21. Wu J. · Adv. Mater. · 2024 · 36
22. 10.1039/D1TB00018G10.1039/D1TB00018G ↗
23. 10.1002/adma.20240904110.1002/adma.202409041 ↗
24. 10.1002/anie.20240037210.1002/anie.202400372 ↗
25. 10.1002/adma.20240272010.1002/adma.202402720 ↗
26. 10.1021/jacs.3c0176510.1021/jacs.3c01765 ↗
27. 10.1038/s41557-023-01367-y10.1038/s41557-023-01367-y ↗
28. 10.1002/adma.20240596610.1002/adma.202405966 ↗
29. 10.1002/adma.20221017910.1002/adma.202210179 ↗
30. 10.1021/jacs.3c0905810.1021/jacs.3c09058 ↗
31. 10.1002/adfm.20241183810.1002/adfm.202411838 ↗
32. 10.1039/C5TC03567H10.1039/C5TC03567H ↗
33. 10.1002/jcc.2288510.1002/jcc.22885 ↗
34. 10.1002/adfm.20220971110.1002/adfm.202209711 ↗
35. 10.1021/acsnano.9b0299310.1021/acsnano.9b02993 ↗
36. 10.1038/s41467-023-40996-210.1038/s41467-023-40996-2 ↗
37. 10.1002/cac2.1253910.1002/cac2.12539 ↗
38. 10.1038/s41467-022-32849-110.1038/s41467-022-32849-1 ↗
39. 10.1016/j.cellimm.2017.10.01510.1016/j.cellimm.2017.10.015 ↗
40. 10.1038/s41423-023-01032-x10.1038/s41423-023-01032-x ↗
41. 10.1186/s13045-024-01524-x10.1186/s13045-024-01524-x ↗
42. 10.1016/j.semcancer.2022.03.01110.1016/j.semcancer.2022.03.011 ↗